The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Early and Long-Term Responses to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
Open accessAbstract
PURPOSE: To determine whether early visual acuity response to ranibizumab in diabetic macular edema is associated with long-term outcome. DESIGN: Post hoc analysis of randomized controlled trial data. METHODS: Pooled data from the ranibizumab plus prompt and deferred laser treatment arms of the Diabetic Retinopathy Clinical Research Network's Protocol I study were used to explore the relationship between early (week 12) and late (weeks 52-156) visual acuity response (mean change from baseline in best-corrected visual acuity [CFB BCVA]; categorized improvement [<5, 5-9, or ≥10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] in BCVA). RESULTS: In the analysis population (340 eyes), <5-, 5- to 9-, and ≥10-letter BCVA improvements occurred in 39.7%, 23.2%, and 37.1% of eyes, respectively, at 12 weeks, and 34.2%, 16.5%, and 49.3% of eyes at 156 weeks. Within each early BCVA response category (<5, 5-9, and ≥10 letters of improvement at 12 weeks), mean CFB BCVA at 52-156 weeks varied by <5 letters from that at 12 weeks. CFB BCVA and <5-letter improvement at 12 weeks showed significant positive and negative association, respectively, with CFB BCVA and ≥10-letter improvement at 52 and 156 weeks. Similar relationships were demonstrated in eyes with baseline BCVA <69 letters, and associations remained significant after multivariate adjustment for potential confounders. CONCLUSIONS: Ranibizumab ± laser therapy resulted in similar rates (∼40%) of suboptimal (<5-letter) and pronounced (≥10-letter) BCVA improvement at 12 weeks. Eyes with suboptimal early BCVA response showed poorer long-term visual outcomes than eyes with pronounced early response (mean improvement 3.0 vs 13.8 letters at 156 weeks).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,428
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Intravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0493 · Cited by 720
Elman, M. J., Bressler, N. M., Qin, H., Beck, R. W., Ferris, F. L., Friedman, S. M., Glassman, A. R., Scott, I. U., Stockdale, C. R., & Sun, J. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.033 · Cited by 573
Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.08.047 · Cited by 562 · cited 1×
“The study follow-up period was subsequently extended to 5 years.(11)”
MethodMichaelides, M., Kaines, A., Hamilton, R. D., Fraser-Bell, S., Rajendram, R., Quhill, F., Boos, C. J., Xing, W., Egan, C., Peto, T., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.03.045 · Cited by 521
Rajendram, R., Fraser-Bell, S., Kaines, A., Michaelides, M., Hamilton, R. D., Esposti, S. D., Peto, T., Egan, C., Bunce, C., Leslie, R. D., et al. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2012.393 · Cited by 389
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., Berliner, A. J., Gao, B., Zeitz, O., Ruckert, R., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.010 · Cited by 385
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment
Elman, M. J., Qin, H., Aiello, L. P., Beck, R. W., Bressler, N. M., Ferris, F. L., Glassman, A. R., Maturi, R. K., & Melia, M. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.022 · Cited by 324
Vitrectomy Outcomes in Eyes with Diabetic Macular Edema and Vitreomacular Traction
(2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.10.040 · Cited by 289
Sophie, R., Lu, N., & Campochiaro, P. A. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.02.036 · Cited by 250
Kiss, S., Liu, Y., Brown, J. G., Holekamp, N. M., Almony, A., Campbell, J. H., & Kowalski, J. W. (2014) · Clinical ophthalmology · doi:10.2147/opth.s60893 · Cited by 112
Self-citationMatsuda, S., Tam, T., Singh, R. P., Kaiser, P. K., Petkovsek, D. S., Carneiro, G., Zanella, M. T., & Ehlers, J. P. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.11.009 · Cited by 82
Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics
Nguyen, Q. D., Agarwal, A. K., Soliman, M. K., Sepah, Y. J., & Diana, V. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52821 · Cited by 44
Wallick, C. J., Hansen, R. N., Campbell, J. H., Kiss, S., Kowalski, J. W., & Sullivan, S. D. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20150730-09 · Cited by 43
Self-citationEl-Shazly, S., El-Bradey, M. H., & Tameesh, M. K. (2013) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12182 · Cited by 39
Cited by
Diabetic Retinopathy: Pathophysiology and Treatments
Wang, W., & Lo, A. C. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061816 · Cited by 1,358
Bressler, N. M., Beaulieu, W. T., Glassman, A. R., Blinder, K. J., Bressler, S. B., Jampol, L. M., Melia, M., Wells, J. A., & for the Diabetic Retinopathy Clinical Research Network (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.6565 · Cited by 343
Zur, D., Iglicki, M., Busch, C., Invernizzi, A., Mariussi, M., Loewenstein, A., Busch, C., Cebeci, Z., Chhablani, J. K., Chaikitmongkol, V., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.031 · Cited by 271
Self-citationAntioxidant Phytochemicals as Potential Therapy for Diabetic Complications
Akpoveso, O.-O. P., Ubah, E. E., & Obasanmi, G. (2023) · Antioxidants · doi:10.3390/antiox12010123 · Cited by 90
Fu, D. J., Mishra, A. V., Quek, C., Balaskas, K., Pontikos, N., Sim, D., Sivaprasad, S., & Faes, L. (2025) · Eye · doi:10.1038/s41433-024-03529-9 · Cited by 14
Metadata
- Authors
- Gonzalez, V. H., Campbell, J., Holekamp, N. M., Kiss, S., Loewenstein, A., Augustin, A. J., Ma, J., Ho, A. C., Patel, V., Whitcup, S. M., & Dugel, P. U.
- Venue
- American Journal of Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 172
- Pages
- 72-79
- ISSN
- 0002-9394 (ISSN-L)
- OpenAlex
- W2520557556
- Cited by
- 352
- References
- 18
- FWCI
- 30.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.